Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087263 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
A Phase 2 study of Gastrointestinal Stromal Tumors, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT06087263 is a Phase 2 study of Gastrointestinal Stromal Tumors that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 95-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06087263, a Phase 2 study of Gastrointestinal Stromal Tumors, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if regorafenib can help to control the disease.
Conditions Studied
Interventions
- DRUG Regorafenib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2034-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06087263
The ClinicalTrials.gov registry entry for NCT06087263 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (97% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Stromal Tumors appearing as the primary indexed condition, and to 1 intervention - of which Regorafenib is the first listed.
NCT06087263 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06087263 about?
NCT06087263 is a clinical study titled "Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.". To learn if regorafenib can help to control the disease.
What is the current status of trial NCT06087263?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2024-06-18. Estimated completion is 2034-07-01.
What conditions does trial NCT06087263 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumors.
What interventions are being tested in trial NCT06087263?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT06087263?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06087263 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
RECRUITING · Phase 2
-
Imatinib TDM in GIST
RECRUITING · Phase 2
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
COMPLETED · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.